Does adding mitomycin to BCG improve disease-free survival for high-risk non-muscle invasive bladder cancer?
For high-risk non-muscle invasive bladder cancer (NMIBC), the standard treatment after surgery is intravesical BCG therapy. Some doctors have considered adding mitomycin (MMC) to BCG to try to improve outcomes. However, a large randomized trial found that adding mitomycin did not improve disease-free survival compared to BCG alone 1. This means that for most patients, BCG alone remains the standard approach.
What the research says
A phase III trial (ANZUP 1301) randomly assigned 501 patients with high-risk NMIBC to receive either BCG plus mitomycin or BCG alone after tumor resection 1. After a median follow-up of 48 months, the 2-year disease-free survival rate was 75% in the combination group versus 71% in the BCG-alone group, a difference that was not statistically significant (hazard ratio 0.87, p=0.3) 1. The combination group also had more instillations and more grade 3-5 adverse events (43 vs 37) 1.
A separate study examined adding electromotive drug administration (EMDA) of mitomycin to a second BCG course in patients who had already failed initial BCG treatment 7. In that setting, combined treatment improved recurrence-free survival for patients with Ta tumors but not for those with T1 tumors 7. However, this was a smaller study (80 patients) and does not apply to first-line therapy.
Other research has explored different combination therapies. For example, a meta-analysis of gemcitabine/docetaxel versus BCG found no significant difference in recurrence-free survival for BCG-naïve patients 2. And a trial comparing BCG to epirubicin in intermediate-risk NMIBC found comparable recurrence and progression rates 3. These studies highlight that BCG alone remains a strong option, and adding another drug does not consistently improve outcomes.
What to ask your doctor
- What is my specific risk category (high-risk, intermediate-risk) and how does that affect my treatment options?
- If I have already received BCG and it failed, could adding mitomycin via EMDA be an option for me?
- What are the potential side effects of BCG alone versus BCG plus mitomycin?
- Are there other intravesical therapies, such as gemcitabine/docetaxel, that might be appropriate for my situation?
- How will my response to treatment be monitored, and what are the next steps if I have a recurrence?
This question is drawn from common patient questions about Urology and answered using cited medical research. We do not provide individualized advice.